Discontinuation of BRAF/MEK Inhibitor Therapy after Long-lasting Response: Clinical Outcomes in Advanced Melanoma
Year: 2025
Type: article
Abstract: Background: BRAF and MEK inhibitors (BRAFi/MEKi) offer high response rates and rapid tumor regression in BRAF-mutant metastatic melanoma. However, objective responses have a median duration of only 12 months. Approximately 24% of patients achieve progression-free survival beyond 3 years, but the impact of discontinuing BRAFi/MEKi after long-lasting responses remains unexplored.
Source: EJC Skin Cancer
Authors: R.H. Døssing, E. Hesselberg, A.B. Clausen, A.A. Luczak, I.M. Svane, H. Schmidt, L. Bastholt, M. Donia, E. Ellebaek
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,340
OpenAlex ID: W4409143479